Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company based in Burlington, MA, presented initial Phase 1 clinical data for LFD-200, its novel subcutaneously administered antibody-drug conjugate (ADC) that delivers a potent glucocorticoid directly to immune cells, at the European Congress of Rheumatology (EULAR) 2026 held in London, UK, from June 3-6, 2026. The data from healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity. Dosing in patients with moderate to severe rheumatoid arthritis (RA) is ongoing, with data expected by year-end 2026.
The Phase 1 study results represent a significant step for Lifordi’s approach of using ADCs—a technology proven in oncology—to treat autoimmune and inflammatory disorders. By targeting immune cells directly, LFD-200 aims to deliver the anti-inflammatory benefits of glucocorticoids while avoiding the systemic side effects, such as cortisol suppression, that limit their chronic use. The absence of cortisol changes in healthy participants suggests that LFD-200 may have a favorable safety profile compared to conventional glucocorticoids. For more details on the announcement, including downloadable images and bios, click here.
Lifordi’s lead ADC, LFD-200, is in a Phase 1 clinical trial for RA and has shown a favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profile in healthy participants, including dose-responsive anti-inflammatory activity without systemic glucocorticoid toxicity. The company has also applied its novel drug delivery approach to other payloads, such as antisense oligonucleotides (ASOs), siRNA, and small molecules. Backed by investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, visit www.lifordi.com and follow on LinkedIn.
